Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$47.40
-1.4%
$47.47
$41.61
$63.33
$97.81B0.3612.77 million shs10.71 million shs
Graphite One Inc. stock logo
GPH
Graphite One
C$0.95
+11.8%
C$0.77
C$0.64
C$1.07
C$96.19M1.0275,989 shs243,562 shs
Organon & Co. stock logo
OGN
Organon & Co.
$9.46
-1.9%
$9.52
$8.01
$23.10
$2.51B0.63.62 million shs3.13 million shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$10.27
-0.4%
$10.62
$6.65
$12.61
$706.39M0.026,169 shs4,037 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-1.38%+1.04%+1.23%-3.73%+9.81%
Graphite One Inc. stock logo
GPH
Graphite One
+11.76%+35.71%+25.00%+3.26%+35.71%
Organon & Co. stock logo
OGN
Organon & Co.
-1.90%-4.83%-4.31%-14.84%-55.31%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-0.39%+2.19%-8.22%+28.05%+16.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
4.8648 of 5 stars
3.23.04.24.02.53.31.3
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AN/AN/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
4.8519 of 5 stars
3.33.01.73.72.33.32.5
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.1322 of 5 stars
3.53.00.00.02.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.32
Hold$57.6921.70% Upside
Graphite One Inc. stock logo
GPH
Graphite One
0.00
N/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
2.50
Moderate Buy$18.0090.27% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00192.11% Upside

Current Analyst Ratings Breakdown

Latest PHAR, BMY, OGN, and GPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$36.00 ➝ $34.00
5/22/2025
Organon & Co. stock logo
OGN
Organon & Co.
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/15/2025
Organon & Co. stock logo
OGN
Organon & Co.
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.00
5/5/2025
Organon & Co. stock logo
OGN
Organon & Co.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.00
5/2/2025
Organon & Co. stock logo
OGN
Organon & Co.
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Inline
4/25/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/25/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/23/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$70.00 ➝ $68.00
4/22/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $55.00
4/22/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.30B2.00$5.81 per share8.16$8.08 per share5.87
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AC$0.01 per share94.17C$0.44 per shareN/A
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.38$4.83 per share1.96$1.83 per share5.17
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M2.37$0.07 per share139.08$3.25 per share3.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-$8.95B$2.6717.757.782.4711.38%87.62%15.98%7/31/2025 (Estimated)
Graphite One Inc. stock logo
GPH
Graphite One
-C$4.90M-C$0.07N/AN/AN/A-10.96%-6.61%N/A
Organon & Co. stock logo
OGN
Organon & Co.
$864M$2.883.282.531.0011.92%227.43%7.34%8/5/2025 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.20N/A342.33N/A-4.14%-6.01%-3.23%7/31/2025 (Estimated)

Latest PHAR, BMY, OGN, and GPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.93N/AN/AN/A$1.55 billionN/A
7/31/2025Q2 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.53N/AN/AN/A$11.32 billionN/A
7/31/2025Q2 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.15N/AN/AN/A$70.36 millionN/A
5/8/2025Q1 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million
5/1/2025Q1 2025
Organon & Co. stock logo
OGN
Organon & Co.
$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billion
4/24/2025Q1 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.50$1.80+$0.30$1.21$10.77 billion$11.20 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.485.23%N/A92.88%17 Years
Graphite One Inc. stock logo
GPH
Graphite One
N/AN/AN/AN/AN/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.080.85%N/A2.78%N/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A

Latest PHAR, BMY, OGN, and GPH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/17/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.625.25%7/3/20257/3/20258/1/2025
5/2/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.020.8%5/12/20255/12/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.65
1.28
1.17
Graphite One Inc. stock logo
GPH
Graphite One
0.02
1.09
0.33
Organon & Co. stock logo
OGN
Organon & Co.
16.49
1.67
1.15
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.39
2.76
2.00

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Graphite One Inc. stock logo
GPH
Graphite One
0.07%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.09%
Graphite One Inc. stock logo
GPH
Graphite One
28.81%
Organon & Co. stock logo
OGN
Organon & Co.
1.96%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
34,1002.04 billion2.03 billionOptionable
Graphite One Inc. stock logo
GPH
Graphite One
20101.25 millionN/ANot Optionable
Organon & Co. stock logo
OGN
Organon & Co.
4,000259.96 million254.86 millionNot Optionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.51 million67.10 millionNot Optionable

Recent News About These Companies

Best Momentum Stocks to Buy for July 17th
New Strong Buy Stocks for July 17th
European Penny Stocks Under €200M Market Cap To Watch

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$47.40 -0.66 (-1.37%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$47.42 +0.02 (+0.05%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Graphite One stock logo

Graphite One CVE:GPH

C$0.95 +0.10 (+11.76%)
As of 07/18/2025 03:41 PM Eastern

Graphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$9.46 -0.18 (-1.87%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$9.47 +0.01 (+0.10%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$10.27 -0.04 (-0.39%)
Closing price 07/18/2025 03:56 PM Eastern
Extended Trading
$10.27 0.00 (0.00%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.